Izilendustat

Izilendustat is a potent inhibitor of prolyl hydroxylase which can stabilize hypoxia inducible factor- 1 alpha (HIF- lα) and hypoxia inducible factor-2 (HIF-2) . Izilendustat has the potential for researching diseases that relate to the body’s inmmune response like colitis and other inflammatory bowel diseases (extracted from patent WO2011057115A1 and WO2011057121A1) [1][1].

Product Specifications

CAS Number

[1303512-02-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HIF/HIF Prolyl-Hydroxylase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/izilendustat.html

Purity

99.20

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(N1CCN(CC(C=CN2CC3=CC=C(Cl)C=C3)=C(O)C2=O)CC1)OC(C)(C)C

Molecular Formula

C22H28ClN3O4

Molecular Weight

433.94

Precautions

H302, H315, H319, H335

References & Citations

[1]Joseph H, et al. Prolyl hydroxylase inhibitors. Patent WO2011057115A1. |[2]Joseph H, et al. Compositions and methods for treating colitis. Patent WO2011057121A1.